[
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_1",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Pediatric Hodgkin lymphoma: cure rates, risk‑adapted chemo±low‑dose RT; prognostic factors & age/sex incidence"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_5",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Childhood Hodgkin lymphoma germline susceptibility: twin concordance, GWAS loci, familial variants"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_0",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Pediatric Hodgkin lymphoma: epidemiology, EBV/immunodeficiency links and treatment evolution"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_2",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_3",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Pediatric Hodgkin lymphoma: male predominance <10, age-specific subtypes, EBV and infection links"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_6",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_4",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_7",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Pediatric Hodgkin lymphoma: EBV prevalence, plasma EBV DNA prognostic pattern, immunodeficiency-associated risk"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_8",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_11",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Early FDG‑PET response predicts outcome in pediatric Hodgkin lymphoma (PET1/PET2)"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_10",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_9",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Pediatric Hodgkin lymphoma: stage IV extranodal sites and adverse prognostic factors"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_15",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Pediatric Hodgkin lymphoma prognostic markers: CHIPS, FDG-PET MTV, CNS involvement, race"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_13",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "EBV association, prevalence, and prognostic significance in childhood Hodgkin lymphoma"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_12",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_14",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Pediatric Hodgkin lymphoma: HIV/transplant immunodeficiency–associated cancer risk and pericardial effusion"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_16",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Pediatric/adolescent Hodgkin lymphoma: chemo±low‑dose nodal RT trials and interim FDG‑PET prognosis"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_17",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Childhood Hodgkin lymphoma: HRS cell morphology and inflammatory microenvironment"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_18",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Pediatric Hodgkin lymphoma immunophenotype: HRS CD30+/CD15±, NLPHL LP CD20+/CD30–"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_19",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Pediatric nodular‑sclerosing Hodgkin lymphoma: lacunar cells, TGF‑β fibrosis, HLA‑II haplotype risk"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_21",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Pediatric NLPHL: male predominance, higher <10y; localized peripheral nonbulky nodes, rare B symptoms"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_22",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_20",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_23",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_24",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Pediatric NLPHL: chemo ± radiotherapy effective; avoid RT alone in prepubescents; late recurrence and treatment‑related mortality"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_25",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Childhood Hodgkin lymphoma immunophenotypes: CD20/B‑cell markers and nodular lymphocyte‑predominant prognostic significance"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_27",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "NLPHL: EBV and IgD+ L&H subsets; pediatric outcomes and microdissection/cfDNA genomic testing"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_28",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Pediatric Hodgkin lymphoma genomic immune evasion: 9p24 (PD-L1/PD-L2) gains, CIITA fusions, JAK-STAT/NF-kB alterations"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_26",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Pediatric lymphocyte‑predominant HL: variant histology, immunophenotype, outcomes"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_30",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Pediatric Hodgkin lymphoma JAK-STAT genomic alterations: SOCS1, STAT6, 9p/JAK2; cfDNA detection rates"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_31",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_32",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_29",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Childhood Hodgkin lymphoma immune-evasion: CIITA fusions, B2M loss, MHC I/II loss by EBV status"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_33",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_34",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Classical Hodgkin lymphoma genomic drivers: JAK‑STAT mutations, PD‑L1 expression, CIITA fusions"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_37",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Childhood Hodgkin lymphoma staging: labs, anatomic CT/MRI, PET‑CT functional imaging"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_35",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Immune‑evasion genomic alterations (9p24.1, CIITA, β2M) and ctDNA in pediatric Hodgkin lymphoma"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_36",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_39",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Bulky disease definitions in pediatric Hodgkin lymphoma: CXR ratio, CT 200 mL, 10 cm"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_38",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_41",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_42",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Pediatric Hodgkin PET‑CT: high marrow sensitivity, lower extranodal concordance, false‑positive thymic/brown fat uptake"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_40",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_43",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_44",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_45",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_47",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Pediatric Hodgkin lymphoma cooperative-group risk stratification and response criteria"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_48",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Interim CT-detected lung nodules in pediatric Hodgkin lymphoma — common, usually nonmalignant"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_46",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_50",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Pediatric advanced HL: BEACOPP response‑adapted; girls COPP/ABV, boys ABVD+IFRT; 5‑yr EFS 94%"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_49",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_52",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Pediatric Hodgkin lymphoma: PET-based complete metabolic response (Lugano 5-point; COG adoption)"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_51",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Pediatric Hodgkin lymphoma interim response–adapted therapy criteria (COG/EuroNet/GPOH)"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_53",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Pediatric Hodgkin lymphoma PET response timing and CR criteria: chemo >=3 weeks, post-RT 8–12 weeks; fibrotic residuals"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_55",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Pediatric Hodgkin lymphoma imaging and prognostic markers: PET/MTV, CRP, staging harmonization"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_54",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Pediatric Hodgkin relapse surveillance: limit CT/PET frequency; biopsy confirmation before therapy change"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_56",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Pediatric Hodgkin lymphoma: FDG‑PET/CT early‑response prognostic and bone marrow staging accuracy"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_58",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Pediatric Hodgkin lymphoma response‑adapted trials and interim qPET assessment"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_57",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Initial staging in pediatric HL: FDG‑PET/CT accuracy for marrow involvement and need for bone marrow biopsy"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_59",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_61",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Pediatric newly diagnosed Hodgkin lymphoma: risk‑adapted multimodality therapy, radiation volume/dose, LD‑ISRT, NLPHL resection"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_60",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_66",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Childhood Hodgkin lymphoma: chemo‑alone vs combined modality; resource‑limited use, alkylator/anthracycline late toxicities"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_62",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_63",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_65",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_64",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_67",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Pediatric Hodgkin lymphoma: risk-adapted, response-based use of chemo±LD-ISRT; EFS benefit"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_68",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Pediatric Hodgkin lymphoma adverse features: mediastinal bulk (>33%), B symptoms, pleural effusion, stage IIIB–IV"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_69",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_71",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Children with NLPHL, favorable IA/IIA: observe after single‑node excision vs AV‑PC ± LD‑IFRT outcomes"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_70",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_72",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Pediatric NLPHL: ABVE‑PC yields high CR/EFS without IFRT; rituximab data limited"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_74",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Pediatric high‑risk Hodgkin lymphoma: central iPET alters RT allocation; INRT/ISRT replace regional fields"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_73",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_75",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_76",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Childhood Hodgkin lymphoma radiation planning: CT simulation, GTV/CTV definitions, postchemo boost for PET-avid/bulky residuals"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_78",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Pediatric Hodgkin RT dosing: 15–25 Gy standard; 30–36 Gy for PET‑avid residual; boosts/IMRT raise late‑effect risk"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_77",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Pediatric Hodgkin lymphoma ISRT organ-at-risk dose limits and PET-directed postchemotherapy radiation"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_81",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Pediatric Hodgkin: IFRT boosts EFS not OS; omit for rapid CR; consolidate refractory/limited recurrences"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_80",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Adjuvant RT in pediatric Hodgkin lymphoma: improves EFS, not OS; early-response dependent, raises late-effect risk"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_79",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Pediatric Hodgkin lymphoma radiotherapy: proton vs IMRT field selection, organ constraints, LD‑IFRT/ISRT chemo‑sparing"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_82",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_84",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Pediatric HL response-based ABVE/DBVE ± IFRT enabling chemotherapy reduction (45–63%)"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_83",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_85",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_87",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_86",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_88",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_89",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_93",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Pediatric Hodgkin lymphoma: early PET–guided IFRT; omission linked to initial-site relapses in slow responders"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_91",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_92",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Childhood Hodgkin lymphoma: PET1 response–guided chemo; 21 Gy IFRT improves PFS in slow responders"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_95",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_94",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_96",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_97",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_90",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_101",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Early-stage pediatric Hodgkin lymphoma: radiation omission after adequate OEPA/AEPA chemotherapy response"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_99",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "EuroNet‑PHL‑C1: pediatric intermediate/advanced HL—RT omission after OEPA response; COPP vs COPDAC gonadotoxicity"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_102",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Pediatric Hodgkin lymphoma: risk‑adapted, response‑based therapy criteria and low‑risk outcomes"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_100",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_98",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_103",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_106",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Adolescent/young‑adult Hodgkin lymphoma prognosis: inferior EFS/OS, mixed‑cellularity high risk"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_108",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Pediatric Hodgkin: chemo regimens vs low‑dose radiotherapy trials, response‑adapted outcomes and late cardiac toxicity"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_105",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Adolescents/young adult Hodgkin lymphoma: inferior EFS by trial, bulky disease, mixed cellularity"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_104",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_107",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Pediatric Hodgkin lymphoma — historical chemo‑radiation regimens and long‑term toxicities"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_109",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_110",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Pediatric nodular lymphocyte‑predominant HL: excision‑only observation, R‑CHOP, long‑term outcomes"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_111",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_114",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Pediatric Hodgkin lymphoma risk‑stratified, response‑adapted regimen outcomes (BEACOPP, CVP, VAMP, P9426)"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_112",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Pediatric Hodgkin lymphoma— involved-node/site vs involved-field RT; proton dosimetry and response‑adapted RT"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_113",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_116",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Children's high‑risk Hodgkin lymphoma: response‑adapted therapy, regimen comparisons, survivorship cardiac risk"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_115",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Early-stage low-risk pediatric Hodgkin lymphoma: response-adapted targeted radiotherapy and QoL"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_117",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_118",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Pediatric relapsed/refractory Hodgkin lymphoma — chemo-based second-line regimens, checkpoint inhibitors, HSCT, ISRT"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_119",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_120",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Brentuximab vedotin in adult relapsed cHL post‑autologous HSCT: FDA indications; phase II CR 34% PR 40%"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_121",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_122",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_123",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_124",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_125",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_126",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_127",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Myeloablative chemo with autologous HSCT for pediatric early relapsed/refractory Hodgkin lymphoma"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_128",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_129",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Childhood relapsed HL: timing- and PET‑based risk stratification directing RT versus autologous HDC/HSCT"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_131",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Pediatric refractory Hodgkin lymphoma: autologous HSCT regimens, prognosis, ISRT indications"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_130",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_133",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_134",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Risk‑ and response‑adapted salvage therapy for relapsed pediatric classical Hodgkin lymphoma"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_135",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_136",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_139",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Pediatric relapsed/refractory Hodgkin lymphoma: autologous vs allogeneic HSCT outcomes (relapse vs TRM)"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_137",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_138",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_132",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_141",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_140",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_142",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_143",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_144",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_145",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Adolescent females — alkylating chemo and pelvic RT risk ovarian insufficiency; ovarian transposition ineffective"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_149",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Childhood Hodgkin survivors: elevated thyroid cancer risk — female, >10‑yr latency, >25 Gy thyroid dose"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_146",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_147",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_148",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_150",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_151",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_152",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_154",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_155",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_157",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_159",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_158",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_156",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_160",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_163",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Pediatric Hodgkin survivors: late thyroid malignancy and radiation/anthracycline cardiac toxicity risk and management"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_161",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Male gonadal dysfunction and infertility risk after pediatric Hodgkin lymphoma therapy"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_164",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_153",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_166",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_165",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_167",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Secondary malignancy risk after pediatric Hodgkin treatment: chemo dose, RT, dexrazoxane"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_168",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Pediatric Hodgkin survivors: chest radiation dose, chemotherapy contribution, breast cancer risk and surveillance"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_162",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Ovarian failure, fertility preservation, and thyroid dysfunction in pediatric HL survivors"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_172",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Childhood Hodgkin lymphoma — lead reviewers and PDQ formal evidence-level process"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_173",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Childhood Hodgkin lymphoma PDQ: citation, copyright, reuse, contact, last updated"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_171",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_169",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Breast cancer risk and surveillance in female childhood Hodgkin survivors — chest RT dose, anthracycline effects"
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_170",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "bd35add17d96481caee57d899078cffa_chunk_174",
    "doc_id": "bd35add17d96481caee57d899078cffa",
    "doc_title": "NCI/PDQ — Childhood Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq",
    "pub_date": "",
    "ctx_header": "Childhood Hodgkin lymphoma NCI PDQ reuse, crediting, and syndication"
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_0",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": "Cancer pain etiology & classification: somatic/visceral/neuropathic, acute/chronic, treatment-related"
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_3",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": "Cancer pain prevalence including advanced-stage, younger age risk, tumor vs treatment causes"
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_1",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": "Cancer pain treatment decision-making: assess contributors, benefit–risk, opioid counseling & safe storage"
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_2",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": "Cancer pain longitudinal titration and opioid safety monitoring"
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_4",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": "Postoperative opioid overprescribing and persistent-use risk after curative cancer surgery; adjuvant chemotherapy increases risk"
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_5",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_7",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": "Cancer treatment pain: EGFR dermatitis, postherpetic neuralgia, hand‑foot syndrome; dexamethasone prevents radiation pain flares"
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_6",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_10",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": "Postoperative opioid prescribing variability and risk of new persistent opioid use"
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_9",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": "Prevalence of cancer pain, anxiety/depression links, and postoperative opioid use patterns"
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_8",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_11",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_13",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": "Total pain in cancer: psychosocial/spiritual contributors; somatization referral"
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_14",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": "Cancer pain pathophysiology: nociceptive (somatic/visceral), neuropathic, plexopathy, allodynia"
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_12",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_16",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": "Breakthrough vs background pain in cancer: incident flares, prevalence, treatment challenges"
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_19",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": "Breast cancer chemotherapy: patient-reported CIPN pain often discordant with clinician assessment, driving dose modifications"
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_15",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_17",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": "Cancer breakthrough pain: prevalence, characteristics and intensity scales (NRS/VAS/categorical)"
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_22",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": "Psychosocial drivers of cancer pain: depression, catastrophizing, low self‑efficacy, chemical coping"
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_20",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_23",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": "Assess current/remote substance use and chemical coping impacting opioid needs and pain sensitivity"
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_25",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": "Pain assessment in cognitively impaired cancer patients: observational tools, caregiver report, cultural/spiritual context"
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_18",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": "Cancer pain assessment: multidimensional tools, timeframes, PPG, special populations"
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_24",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": "Cancer pain prognostic tools (ECS‑CP, CPPS) and assessment adaptations for children/cognitive impairment"
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_26",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_29",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_27",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": "Psychosocial influences, coping self-efficacy, and patient-reported outcomes in cancer pain (ethnic differences)"
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_21",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_30",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": "Cancer pain assessment: ECS‑CP classification and tools for cognitively impaired and pediatric patients"
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_31",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": "Pediatric pain scales and validity; pharmacologic analgesic classes (acetaminophen, NSAIDs, opioids, adjuvants)"
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_28",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": "Catastrophizing, coping, and alcoholism screening: risks for chronic cancer pain and long-term opioid use"
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_34",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_35",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_36",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_38",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_37",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_32",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_40",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": "Opioid‑induced hyperalgesia in cancer: diagnosis, opioid rotation, methadone, pregabalin"
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_33",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_41",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_42",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_44",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": "Opioid-induced endocrinopathy: testosterone/estrogen replacement risks, CYP/hepatic considerations"
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_46",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": "Opioid selection and rotation: renal/hepatic impairment, adverse effects, route changes"
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_39",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_45",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_43",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_49",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_50",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": "Pediatric cancer survivors: CDC opioid guideline reduced prescriptions but risked access"
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_48",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_47",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": "Opioid-rotation selection for cancer pain: reasons (uncontrolled pain, OIN) and outpatient success"
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_51",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": "Older adults with poor‑prognosis cancer: Black/Hispanic opioid prescribing disparities, REMS/PDMP barriers"
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_54",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": "Oncology opioid aberrant behaviors and structured therapy safeguards"
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_55",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_56",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_52",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_53",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": "Opioid initiation in cancer patients: assess addiction and abuse risk; distinguish tolerance, substance use disorder, aberrant behaviors"
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_60",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_57",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_63",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": "Strong opioid formulations and rotation: transdermal agents, equianalgesic ratios, cachexia/end‑of‑life"
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_59",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": "Bisphosphonates for bone‑metastasis pain: analgesic benefit, ASCO guidance, ibandronate vs radiotherapy"
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_62",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": "Advanced-cancer pain: NSAID/paracetamol adjuncts and strong-opioid comparative effectiveness/adherence"
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_61",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": "Cancer pain pharmacotherapy evidence: opioids, acetaminophen, NSAIDs, adjuvants"
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_64",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": "Cancer pain opioid formulations, PK, rotation, methadone safety and rapid‑onset agents"
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_65",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_66",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_67",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_68",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": "Opioid adverse effects and management—OIC, androgen deficiency, renal dosing in CKD"
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_70",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_71",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": "Oncologic opioid risks: postoperative persistent use, chemical coping, aberrant-use predictors"
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_73",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_58",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": "Corticosteroid adjuvant analgesia in cancer pain: indications, dosing, tapering, dexamethasone preference"
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_69",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": "Cancer opioid rotation best practices, renal dosing, and prescribing trends"
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_74",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": "Zoledronic acid and denosumab for metastatic bone pain: analgesic efficacy and ONJ risk"
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_78",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": "Interdisciplinary palliative/supportive care referral for refractory cancer pain; early integration reduces symptom burden, improves QOL"
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_76",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_77",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_79",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": "Palliative radiotherapy for cancer pain: single‑fraction bone metastases dosing and selection predictors"
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_72",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": "Cancer pain opioid management: universal precautions, UDT, adjuncts"
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_75",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": "Interventional approaches for refractory cancer pain — nerve blocks, neuroaxial, cordotomy, celiac plexus"
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_80",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_82",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_85",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_86",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_87",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_84",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": "Neural blockade, neuraxial/implantable therapies, cordotomy in refractory cancer pain"
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_88",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_83",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_90",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_81",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_89",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": "Metastatic bone pain: mechanisms, incident pain, opioids, NSAID/steroid adjuncts, orthopedic referral"
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_91",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_92",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_96",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_97",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_95",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_93",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": "Postoperative neuropathic pain: mixed evidence for preop gabapentinoids/SNRIs in mastectomy/thoracotomy"
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_94",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": "Agents causing cancer therapy–related peripheral neuropathy: prevalence, chronicity, dose‑limiting"
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_99",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_98",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_100",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_101",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_103",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_105",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_104",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": "Cancer bone pain assessment and outcomes; NSAID/paracetamol adjuncts and gabapentin for neuropathic pain"
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_108",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": "CIPN risk factors, genetic predictors, disparities and management in taxane/platinum-treated adults"
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_102",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_106",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_111",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": "Geriatric cancer pain: analgesic pharmacology, hepatic impairment, high‑risk medication risks"
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_110",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_112",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_113",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": "Editorial review, evidence‑level designations, and citation/contact guidance for PDQ Cancer Pain"
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_109",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_1",
    "doc_id": "9998fea73ab5464e87515a4e9d37e447",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_3",
    "doc_id": "9998fea73ab5464e87515a4e9d37e447",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "pub_date": "",
    "ctx_header": "Women with dense breasts: evidence lacking for supplemental ultrasound or MRI; biennial mammography from 40"
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_107",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_4",
    "doc_id": "9998fea73ab5464e87515a4e9d37e447",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "pub_date": "",
    "ctx_header": "USPSTF final: biennial screening mammography ages 40–74, Grade B; ≥75 evidence insufficient; equitable follow-up urged"
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_0",
    "doc_id": "9998fea73ab5464e87515a4e9d37e447",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "pub_date": "",
    "ctx_header": "USPSTF final: biennial mammography from age 40 for all women"
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_7",
    "doc_id": "9998fea73ab5464e87515a4e9d37e447",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "pub_date": "",
    "ctx_header": "Individualized clinical decision-making; evidence reviews, modeling, research gaps, provider/patient resources"
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_5",
    "doc_id": "9998fea73ab5464e87515a4e9d37e447",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "946c695575ec479fb18ffaca8536c13e_chunk_114",
    "doc_id": "946c695575ec479fb18ffaca8536c13e",
    "doc_title": "NCI/PDQ — Cancer Pain (PDQ®)–Health Professional Version",
    "source_org": "NCI/PDQ",
    "source_url": "https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq",
    "pub_date": "",
    "ctx_header": "PDQ content and image licensing, citation, syndication, insurance/contact disclaimers"
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_2",
    "doc_id": "9998fea73ab5464e87515a4e9d37e447",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "pub_date": "",
    "ctx_header": "Biennial screening 40–74 (B grade); urgent research on disparities, dense breasts, older women"
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_10",
    "doc_id": "9998fea73ab5464e87515a4e9d37e447",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "pub_date": "",
    "ctx_header": "Cisgender women and all AFAB persons ≥40 at average risk — excludes BRCA, chest radiation in youth, prior breast cancer/high‑risk lesions"
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_11",
    "doc_id": "9998fea73ab5464e87515a4e9d37e447",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_8",
    "doc_id": "9998fea73ab5464e87515a4e9d37e447",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "pub_date": "",
    "ctx_header": "Breast cancer screening recommendation framework: benefit–harm balance, excludes cost, equity, individualized care"
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_6",
    "doc_id": "9998fea73ab5464e87515a4e9d37e447",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_9",
    "doc_id": "9998fea73ab5464e87515a4e9d37e447",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "pub_date": "",
    "ctx_header": "US breast cancer burden: mortality, incidence trends (age 40–49), racial stage disparities"
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_14",
    "doc_id": "9998fea73ab5464e87515a4e9d37e447",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "pub_date": "",
    "ctx_header": "Black women — elevated triple‑negative breast cancer incidence; screening detection limits, treatment delays"
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_12",
    "doc_id": "9998fea73ab5464e87515a4e9d37e447",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "pub_date": "",
    "ctx_header": "Screen-detected DCIS management: individualized treatment, overdiagnosis uncertainty"
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_16",
    "doc_id": "9998fea73ab5464e87515a4e9d37e447",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "pub_date": "",
    "ctx_header": "Dense-breast women: supplemental ultrasound/MRI after normal mammogram — insufficient evidence of benefit"
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_15",
    "doc_id": "9998fea73ab5464e87515a4e9d37e447",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "pub_date": "",
    "ctx_header": "Racial disparities in follow-up and endocrine therapy adherence; screening benefit unclear ≥75"
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_13",
    "doc_id": "9998fea73ab5464e87515a4e9d37e447",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "pub_date": "",
    "ctx_header": "Breast cancer mortality disparity in Black women: segregation, toxic environments, healthcare determinants"
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_17",
    "doc_id": "9998fea73ab5464e87515a4e9d37e447",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_19",
    "doc_id": "9998fea73ab5464e87515a4e9d37e447",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "pub_date": "",
    "ctx_header": "CISNET modeling of screening benefits/harms by age, modality, interval, with Black‑specific disparity models"
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_18",
    "doc_id": "9998fea73ab5464e87515a4e9d37e447",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_22",
    "doc_id": "9998fea73ab5464e87515a4e9d37e447",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_24",
    "doc_id": "9998fea73ab5464e87515a4e9d37e447",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_20",
    "doc_id": "9998fea73ab5464e87515a4e9d37e447",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "pub_date": "",
    "ctx_header": "Age‑stratified RCT mammography mortality reductions; limited diversity, no all‑cause benefit"
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_23",
    "doc_id": "9998fea73ab5464e87515a4e9d37e447",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_26",
    "doc_id": "9998fea73ab5464e87515a4e9d37e447",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_27",
    "doc_id": "9998fea73ab5464e87515a4e9d37e447",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_29",
    "doc_id": "9998fea73ab5464e87515a4e9d37e447",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "pub_date": "",
    "ctx_header": "Screening women: interval cancer rates with DBT vs digital mammography (RCTs & nonrandomized)"
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_21",
    "doc_id": "9998fea73ab5464e87515a4e9d37e447",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_25",
    "doc_id": "9998fea73ab5464e87515a4e9d37e447",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "pub_date": "",
    "ctx_header": "Biennial screening (ages 40–74): DBT ≈ digital mammography; no MRI/US evidence; high false-positives"
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_31",
    "doc_id": "9998fea73ab5464e87515a4e9d37e447",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_32",
    "doc_id": "9998fea73ab5464e87515a4e9d37e447",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "pub_date": "",
    "ctx_header": "Supplemental ultrasonography vs digital mammography (ages 40–49): similar interval cancer rates; increased biopsies and false-positives"
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_33",
    "doc_id": "9998fea73ab5464e87515a4e9d37e447",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_28",
    "doc_id": "9998fea73ab5464e87515a4e9d37e447",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "pub_date": "",
    "ctx_header": "Breast screening interval: interval cancer rates, false-positives, overdiagnosis (women 40–74)"
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_36",
    "doc_id": "9998fea73ab5464e87515a4e9d37e447",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "pub_date": "",
    "ctx_header": "Breast cancer mortality disparities in Black women — biomarker causes and research need"
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_30",
    "doc_id": "9998fea73ab5464e87515a4e9d37e447",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "pub_date": "",
    "ctx_header": "Women 40–74: DBT vs digital mammography — 10‑yr false‑positive and biopsy rates (annual vs biennial)"
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_34",
    "doc_id": "9998fea73ab5464e87515a4e9d37e447",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_38",
    "doc_id": "9998fea73ab5464e87515a4e9d37e447",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "pub_date": "",
    "ctx_header": "Average-risk women mammography: ACS/ACOG/ACR age-interval disparities vs USPSTF"
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_39",
    "doc_id": "9998fea73ab5464e87515a4e9d37e447",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "pub_date": "",
    "ctx_header": "Authorship list, COI recusals, JAMA citation for breast cancer screening"
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_41",
    "doc_id": "9998fea73ab5464e87515a4e9d37e447",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "pub_date": "",
    "ctx_header": "AHRQ involvement vs USPSTF independence; copyright, reuse, advertising prohibition"
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_43",
    "doc_id": "9998fea73ab5464e87515a4e9d37e447",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "pub_date": "",
    "ctx_header": "SEER-derived female breast cancer incidence statistics and supporting guideline citations"
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_42",
    "doc_id": "9998fea73ab5464e87515a4e9d37e447",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "pub_date": "",
    "ctx_header": "Breast cancer screening: reuse/copyright limits, Section 1140 citation requirement"
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_44",
    "doc_id": "9998fea73ab5464e87515a4e9d37e447",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "pub_date": "",
    "ctx_header": "Biennial mammography ages 40–74: moderate net benefit; supplemental ultrasound/MRI evidence insufficient"
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_40",
    "doc_id": "9998fea73ab5464e87515a4e9d37e447",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "pub_date": "",
    "ctx_header": "USPSTF breast‑cancer screening COIs, honoraria/reimbursements and AHRQ operational funding"
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_45",
    "doc_id": "9998fea73ab5464e87515a4e9d37e447",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_37",
    "doc_id": "9998fea73ab5464e87515a4e9d37e447",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "pub_date": "",
    "ctx_header": "USPSTF rationale: modeling supports biennial mammography ages 40–74; harms weighed"
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_35",
    "doc_id": "9998fea73ab5464e87515a4e9d37e447",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "pub_date": "",
    "ctx_header": "Supplemental MRI/ultrasound for dense breasts — insufficient evidence; I statement neither for nor against"
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_46",
    "doc_id": "9998fea73ab5464e87515a4e9d37e447",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "pub_date": "",
    "ctx_header": "Breast cancer screening research gaps—DCIS prognosis, overdiagnosis, Black women equity"
  },
  {
    "chunk_id": "9998fea73ab5464e87515a4e9d37e447_chunk_47",
    "doc_id": "9998fea73ab5464e87515a4e9d37e447",
    "doc_title": "USPSTF — Breast Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_0",
    "doc_id": "4761a1c395e94f8cb8bb00208d8a04af",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_1",
    "doc_id": "4761a1c395e94f8cb8bb00208d8a04af",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_5",
    "doc_id": "4761a1c395e94f8cb8bb00208d8a04af",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "pub_date": "",
    "ctx_header": "Age-driven CRC risk and disparities; offer screening to all adults ≥45"
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_3",
    "doc_id": "4761a1c395e94f8cb8bb00208d8a04af",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "pub_date": "",
    "ctx_header": "Colorectal cancer screening net-benefit: ages 50–75 high-certainty; 45–49 moderate"
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_4",
    "doc_id": "4761a1c395e94f8cb8bb00208d8a04af",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "pub_date": "",
    "ctx_header": "Colorectal cancer screening adults 76–85 previously screened: small net benefit; stool‑HS, colonoscopy, CT colonography, sigmoidoscopy; excludes serum/urine/capsule"
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_2",
    "doc_id": "4761a1c395e94f8cb8bb00208d8a04af",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_6",
    "doc_id": "4761a1c395e94f8cb8bb00208d8a04af",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "pub_date": "",
    "ctx_header": "Stool-based CRC screening (FIT, sDNA-FIT, gFOBT): accuracy, FDA sDNA approval, colonoscopy follow-up"
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_7",
    "doc_id": "4761a1c395e94f8cb8bb00208d8a04af",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_9",
    "doc_id": "4761a1c395e94f8cb8bb00208d8a04af",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "pub_date": "",
    "ctx_header": "Adults ≥86: screening unlikely to benefit; test-specific interval recommendations"
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_12",
    "doc_id": "4761a1c395e94f8cb8bb00208d8a04af",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "pub_date": "",
    "ctx_header": "CRC screening in Black adults: systems to ensure adherence, repeated home stool‑based testing and colonoscopy follow‑up"
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_8",
    "doc_id": "4761a1c395e94f8cb8bb00208d8a04af",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_10",
    "doc_id": "4761a1c395e94f8cb8bb00208d8a04af",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_13",
    "doc_id": "4761a1c395e94f8cb8bb00208d8a04af",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_17",
    "doc_id": "4761a1c395e94f8cb8bb00208d8a04af",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "pub_date": "",
    "ctx_header": "Colonoscopy vs CT colonography accuracy for ≥10 mm adenomas in adults; age-related sensitivity"
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_11",
    "doc_id": "4761a1c395e94f8cb8bb00208d8a04af",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_15",
    "doc_id": "4761a1c395e94f8cb8bb00208d8a04af",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "pub_date": "",
    "ctx_header": "CISNET modeling of screening benefits/harms by start/stop age, race; single-test accuracy vs colonoscopy"
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_14",
    "doc_id": "4761a1c395e94f8cb8bb00208d8a04af",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_18",
    "doc_id": "4761a1c395e94f8cb8bb00208d8a04af",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_16",
    "doc_id": "4761a1c395e94f8cb8bb00208d8a04af",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "pub_date": "",
    "ctx_header": "Diagnostic accuracy of gFOBT, FIT, sDNA‑FIT vs colonoscopy; age effects on specificity"
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_22",
    "doc_id": "4761a1c395e94f8cb8bb00208d8a04af",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "pub_date": "",
    "ctx_header": "Screening colonoscopy harms: bleeding/perforation rates, age-related and bowel‑prep risks"
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_19",
    "doc_id": "4761a1c395e94f8cb8bb00208d8a04af",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "pub_date": "",
    "ctx_header": "Prospective cohort colorectal cancer screening outcomes: colonoscopy, FIT; age-specific mortality"
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_23",
    "doc_id": "4761a1c395e94f8cb8bb00208d8a04af",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "pub_date": "",
    "ctx_header": "Harms of flexible sigmoidoscopy, follow‑up colonoscopy, and CT colonography (radiation, overdetection)"
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_25",
    "doc_id": "4761a1c395e94f8cb8bb00208d8a04af",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_26",
    "doc_id": "4761a1c395e94f8cb8bb00208d8a04af",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "pub_date": "",
    "ctx_header": "sDNA‑FIT interval 1–3 years; no evidence to rank CRC screening tests; hybrids and <50 research needed"
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_27",
    "doc_id": "4761a1c395e94f8cb8bb00208d8a04af",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "pub_date": "",
    "ctx_header": "Evidence gaps: Black adult disparities and effectiveness of sDNA‑FIT, CT colonography, serum/urine/capsule tests"
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_24",
    "doc_id": "4761a1c395e94f8cb8bb00208d8a04af",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "pub_date": "",
    "ctx_header": "Modeled lifetime colonoscopies and complications per 1,000 screened (ages 45–75)"
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_20",
    "doc_id": "4761a1c395e94f8cb8bb00208d8a04af",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_21",
    "doc_id": "4761a1c395e94f8cb8bb00208d8a04af",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "pub_date": "",
    "ctx_header": "Adults 45–75 CRC screening (CISNET): life‑years gained, cases/deaths averted per 1000, colonoscopy harm rates"
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_32",
    "doc_id": "4761a1c395e94f8cb8bb00208d8a04af",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "pub_date": "",
    "ctx_header": "Colorectal cancer incidence, early-onset trends and guideline references"
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_28",
    "doc_id": "4761a1c395e94f8cb8bb00208d8a04af",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_31",
    "doc_id": "4761a1c395e94f8cb8bb00208d8a04af",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "pub_date": "",
    "ctx_header": "Colorectal cancer screening: copyright, reuse, citation and endorsement restrictions"
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_33",
    "doc_id": "4761a1c395e94f8cb8bb00208d8a04af",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "pub_date": "",
    "ctx_header": "Adults 50–75: annual high‑sensitivity gFOBT — mortality reduction, colonoscopy follow‑up harms, adherence logistics"
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_35",
    "doc_id": "4761a1c395e94f8cb8bb00208d8a04af",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_36",
    "doc_id": "4761a1c395e94f8cb8bb00208d8a04af",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_39",
    "doc_id": "4761a1c395e94f8cb8bb00208d8a04af",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "pub_date": "",
    "ctx_header": "Adults ≥76 screening harms: higher colonoscopy serious adverse events, increased extracolonic CT colonography findings"
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_34",
    "doc_id": "4761a1c395e94f8cb8bb00208d8a04af",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_38",
    "doc_id": "4761a1c395e94f8cb8bb00208d8a04af",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "pub_date": "",
    "ctx_header": "Adults 45–49 colorectal screening: test accuracy, moderate benefit, lower procedural harms"
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_29",
    "doc_id": "4761a1c395e94f8cb8bb00208d8a04af",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "pub_date": "",
    "ctx_header": "Colorectal cancer screening: USPSTF members, COI disclosures, AHRQ funding"
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_30",
    "doc_id": "4761a1c395e94f8cb8bb00208d8a04af",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "pub_date": "",
    "ctx_header": "Colorectal cancer screening: AHRQ funder role, USPSTF independence, clinician individualization"
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_40",
    "doc_id": "4761a1c395e94f8cb8bb00208d8a04af",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "dba3b1192d9c4e3c8a23cfdb618bb415_chunk_1",
    "doc_id": "dba3b1192d9c4e3c8a23cfdb618bb415",
    "doc_title": "NIH/NHLBI — Asthma Management Guidelines: Focused Updates 2020",
    "source_org": "NIH/NHLBI",
    "source_url": "https://www.nhlbi.nih.gov/health-topics/asthma-management-guidelines-2020-updates",
    "pub_date": "",
    "ctx_header": ""
  },
  {
    "chunk_id": "4761a1c395e94f8cb8bb00208d8a04af_chunk_37",
    "doc_id": "4761a1c395e94f8cb8bb00208d8a04af",
    "doc_title": "USPSTF — Colorectal Cancer: Screening",
    "source_org": "USPSTF",
    "source_url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
    "pub_date": "",
    "ctx_header": "Adults: CRC screening accuracy and net benefit by age 45–49, 50–75, 76–85"
  },
  {
    "chunk_id": "dba3b1192d9c4e3c8a23cfdb618bb415_chunk_0",
    "doc_id": "dba3b1192d9c4e3c8a23cfdb618bb415",
    "doc_title": "NIH/NHLBI — Asthma Management Guidelines: Focused Updates 2020",
    "source_org": "NIH/NHLBI",
    "source_url": "https://www.nhlbi.nih.gov/health-topics/asthma-management-guidelines-2020-updates",
    "pub_date": "",
    "ctx_header": "Asthma long-term controller: inhaled corticosteroids ± LAMA; indoor trigger mitigation"
  }
]